Personalis NeXT Personal MRD test posts 100% sensitivity for colorectal cancer relapse in VICTORI study at ASCO 2026

Personalis

Personalis

PSNL

0.00
  • Personalis highlighted clinical data already presented at ASCO 2026 on its NeXT Personal MRD blood test across multiple solid tumors.
  • In a prospective colorectal cancer study, the test identified recurrence earlier than standard imaging, supporting use in post-surgery surveillance decisions.
  • A lung cancer analysis showed the assay detected very low-level residual disease that correlated with higher relapse risk, pointing to earlier intervention opportunities.
  • Additional ASCO presentations in ovarian, endometrial, and melanoma indicated ctDNA detection or clearance aligned with progression risk, supporting broader clinical adoption.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606020600BIZWIRE_USPR_____20260602_BW445979) on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.